We received a presenatation on KBV's quality and efficiency goals.
Some of the problem areas in Germany pharmacy include non-adherence (50% of those prescribed are not taken), and polypharmacy. A new pilot study was recently started to develop and deliver their concept of medication management.
In the afternoon, we crossed the street to visit the G-BA (Gemeinsamer Bundesausschuss), which is the federal joint commission, and learned more about their pharmaceutical department. The G-BA is the highest decision-making body and self-governing system in Germany.
The newly developed early benefit assessment (AMNOG) was described, and aims for fair prices for medication products and pricing within their statutory health insurance (SHI).
After the work was done for the day, the ladies went shopping.
Dinner was at the Augustina.